Skip to main content

Table 1 Baseline Characteristics

From: Going beyond the mean: economic benefits of myocardial infarction secondary prevention

 

All

not pre-exposed to prophylactic drugs

pre-exposed to prophylactic drugs

N

1840 (100%)

542 (100%)

1298 (100%)

Demographics

 Median age [interquartile range]

73.0 [61.5; 82.0]

61.0 [53.0; 73.0]

76.0 [67.0; 84.0]

 Female sex

654 (35.5%)

157 (29.0%)

497 (38.3%)

 Living in French/Italian speaking cantons (vs. Swiss German)

466 (25.3%)

136 (25.1%)

330 (25.4%)

 Living in urban region (vs. rural/suburban)

1391 (75.6%)

413 (76.2%)

978 (75.3%)

Insurance Characteristics

 Annual deductible > 500 Swiss Francs

240 (13.0%)

147 (27.1%)

93 (7.2%)

 Having supplementary insurance

1408 (76.5%)

398 (73.4%)

1010 (77.8%)

 Having a managed care contract

741 (40.3%)

253 (46.7%)

488 (37.6%)

Prior medication use for chronic co-morbidities

 Cancer

33 (1.8%)

7 (1.3%)

26 (2.0%)

 Cardiovascular diseases

1361 (74.0%)

63 (11.6%)

1298 (100.0%)

 Type 1 or type 2 diabetes

382 (20.8%)

39 (7.2%)

343 (26.4%)

 Hypertension

709 (38.5%)

48 (8.9%)

661 (50.9%)

 Median number of chronic comorbidities [interquartile range]

3.0 [2.0; 3.0]

3.0 [2.0; 3.0]

3.0 [3.0; 3.0]

High-intensity statin use prior index date

694 (37.7%)

45 (8.3%)

649 (50.0%)

Inpatient stays prior to index date

428 (23.3%)

50 (9.2%)

378 (29.1%)

High outpatient medication costs prior to index date

154 (8.4%)

24 (4.4%)

130 (10.0%)

Treatments received within 30 days after index date

 Aspirin

1212 (65.9%)

455 (83.9%)

757 (58.3%)

 P2Y12 inhibitors

1191 (64.7%)

406 (74.9%)

785 (60.5%)

 ACE/ARB

1144 (62.2%)

366 (67.5%)

778 (59.9%)

 Betablocker

1117 (60.7%)

358 (66.1%)

759 (58.5%)

 High-intensity statins

990 (53.8%)

386 (71.2%)

604 (46.5%)

Combination treatments received

 Three drug classesa

486 (26.4%)

161 (29.7%)

325 (25.0%)

 Four drug classesa

595 (32.3%)

236 (43.5%)

359 (27.7%)

Clinical outcomes 390 days after index date (30 day assessment period and 360 day outcome observation period)

 Having died after index date

175 (9.5%)

24 (4.4%)

151 (11.6%)

 Having had inpatient hospital stays after index date

735 (39.9%)

146 (26.9%)

589 (45.4%)

  1. a Four class treatments include high intensity statins, beta-blockers, ACE/ARB and either Aspirin or P2Y12 inhibitors. Three class treatments only include three of the four drug classes